Bone Biologics Corp Stock Fundamentals
| BBLGW Stock | USD 28.49 0.00 0.00% |
Bone Biologics Corp fundamentals help investors to digest information that contributes to Bone Biologics' financial success or failures. It also enables traders to predict the movement of Bone Stock. The fundamental analysis module provides a way to measure Bone Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bone Biologics stock.
At this time, Bone Biologics' Other Operating Expenses is fairly stable compared to the past year. EBITDA is likely to climb to about 503.6 K in 2024, despite the fact that EBIT is likely to grow to (8.5 M). Bone | Select Account or Indicator |
Bone Biologics Corp Company EBITDA Analysis
Bone Biologics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Bone Biologics EBITDA | 479.57 K |
Most of Bone Biologics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bone Biologics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Bone Ebitda
Ebitda |
|
According to the company disclosure, Bone Biologics Corp reported earnings before interest,tax, depreciation and amortization of 479.57 K. This is 99.95% lower than that of the Health Care Equipment & Supplies sector and 99.93% lower than that of the Health Care industry. The ebitda for all United States stocks is 99.99% higher than that of the company.
Bone Biologics Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bone Biologics's current stock value. Our valuation model uses many indicators to compare Bone Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bone Biologics competition to find correlations between indicators driving Bone Biologics's intrinsic value. More Info.Bone Biologics Corp is rated fourth in return on equity category among its peers. It also is rated fourth in return on asset category among its peers . At this time, Bone Biologics' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Bone Biologics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Bone EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bone Biologics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bone Biologics could also be used in its relative valuation, which is a method of valuing Bone Biologics by comparing valuation metrics of similar companies.Bone Biologics is currently under evaluation in ebitda category among its peers.
Bone Biologics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bone Biologics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bone Biologics' managers, analysts, and investors.Environmental | Governance | Social |
Bone Fundamentals
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.57 | ||||
| Number Of Shares Shorted | 376 | ||||
| EBITDA | 479.57 K | ||||
| Net Income | (8.95 M) | ||||
| Cash And Equivalents | 4.44 K | ||||
| Total Debt | 831.4 K | ||||
| Book Value Per Share | 5.44 X | ||||
| Cash Flow From Operations | (9.56 M) | ||||
| Earnings Per Share | (0.14) X | ||||
| Beta | 0.74 | ||||
| Total Asset | 3.74 M | ||||
| Retained Earnings | (80.91 M) | ||||
| Working Capital | 2.91 M | ||||
| Net Asset | 3.74 M |
About Bone Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bone Biologics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bone Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bone Biologics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 901.2 K | 602.3 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.